A site-specific labeling method was developed in which sulfhydryl groups of a murine IgG2a anti-ovarian monoclonal antibody, 5G6.4, were biotinylated with N-iodoacetyl-N'-biotinylhexylenediamine (Compound 1) followed partial reduction of disulfide bonds with dithiothreitol. Reaction of 1-alkylated 5G6.4 with 125I-streptavidin gave immunoreactive streptavidin-1-biotinylated complexes. Radio-fast protein liquid chromatography data were consistent with the formation of a stable monovalent streptavidin-half-antibody complex as the major species. In vivo specific localization of these radioantibody conjugates to human tumor xenografts of ovarian carcinoma was confirmed by a comparative biodistribution study in nude mice using as a control the nonspecific 125I-streptavidin-1-alkylated UPC-10 (an irrelevant IgG2a monoclonal antibody) complex prepared analogously as described above. Tumor uptake for radiolabeled 5G6.4 [0.279 ± 0.041% (SE) kg injection dose/g) was significantly greater [P < 0.025] than for UPC-10 [0.165 ± 0.027% kg injection dose/g]. The tumor:blood ratio (7.38 ± 1.285) for 5G6.4 was ~ 3 times that for UPC-10 (2.48 ± 0.708, P < 0.01). This sulfhydryl site-directed approach demonstrated that reduced disulfides of monoclonal antibodies are viable sites for attaching labels without significant loss of in vitro and in vivo immunoreactivity.
|Original language||English (US)|
|Issue number||3 SUPPL.|
|State||Published - 1990|
ASJC Scopus subject areas
- Cancer Research